Editorial

Variation in primary Sjögren’s syndrome care among European countries

C. Seghieri1, E. Lupi1, T.P. Exarchos2, F. Ferro3, A.G. Tzioufas4, C. Baldini3

The geographic variation in spending, utilisation and quality of care, across and within countries is well documented. Part of this geographic variation is linked to differences in population health and needs. However, some of the variation may be unwarranted and driven by factors other than patients’ health needs and preferences, including professional discretion, the availability and distribution of resources, differences in the organisation or delivery of care and in payment models (1). International and national comparative research is therefore needed in order to be able to tackle unwarranted variations, to identify best practices and, ultimately, create significant value in healthcare (2). Data benchmarking also contributes to engage the multi-specialty professionals (e.g. specialists and GPs) involved in the care of cohort of patients and hold them accountable for the patients that have in common. This is particularly true for patients with long-term chronic diseases who are likely to receive suboptimal care with large variations in the provision of evidence-based treatments and services, and gaps in the disease management due fragmentation of care and poor coordination among the different care settings (3, 4).

Primary Sjögren’s syndrome (pSS) is a heterogeneous, complex systemic autoimmune disorder typically characterised by salivary and lacrimal inflammation and dysfunction. During the disease course, several organs and systems may be involved (5-7) and, in a minority of cases, lymphoproliferative complications may also occur, with mucosa-associated lymphoid tissue (MALT) lymphoma of salivary glands being the most frequent haematological type of non-Hodgkin’s lymphoma (NHL) detected (8).

Although pSS does not, in general, impair life expectancy and is widely considered as a benign disease, the impact of the disease is not neglectable, imposing a considerable burden on patients’ lives (9). Indeed, as recently highlighted by the European Reference Network (ERN) dedicated to Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET), although clinical practice guidelines on diagnosis and management of SS have been published, a number of unmet needs for pSS are still to be addressed (10). From this perspective, misdiagnosis is still common since the mean length of time between the onset of symptoms and diagnosis is about 7 years, biomarkers of disease severity and outcome are uncertain (11), and pSS patients are likely to experience worse quality of life, to use more care services and report higher out-of-pocket expenses compared to controls (12-16). The main factors contributing to suboptimal levels of care and treatments include the lack of awareness and knowledge of the condition among the various healthcare professionals encountered by pSS patients, gaps in evidence-based therapeutic guidelines and, more in general, in evidence-based clinical guidelines for the management of pSS (17, 18). Nonetheless, to the best of our knowledge, the currently available evidence on the sources and effects of variations in the care of pSS is scarce and of limited generalisability in the different European countries. Greater insight is needed with regard to the mechanisms that link the performance and organisation of the different healthcare systems and the experience and quality of life of patients through the use of comparable information across and within health systems.

The EU funded HarmonicSS project
European countries through the clinical centres and patient and medical associations. Analysis of the data will contribute to explain variations in pSS care at different levels (different care providers and patients) by comparing patients’ experience and quality of life, local medical practice and the way the care to pSS patients is organised and delivered.

To this end, HarmonicSS novel data will contribute to the knowledge on the pSS burden in Europe by reporting on unwarranted variations in health care use, spending, and quality, taking the different contexts into account. Comparative quality reporting will contribute to identify good practices to enhance the applicability of the findings, to engage the professionals involved in the care of pSS patients by holding them accountable for the patients they have in common and responsible for efficient utilisation of resources with the ultimate goal to shift to value-based healthcare (19).

References